Novartis Ag

Novartis Pharma Gmbh

Timothy Wright

Hermann Gram

Thomas Jung

Trevor Mundel

Phil Lowe

Peter Gergely

Philip Lowe

Syed Sohail Ahmed

Marco Londei

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds such as IL-1&#x3b2; antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.

Methods of using IL-1&#x3b2; compounds to treat familial mediterranean fever (FMF)

The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim, in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies and inclusion body myositis.

Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation

This invention relates to methods employing IL-1&#x3b2;-ligand/IL-1 receptor disrupting compounds (herein referred to as 'IL-1beta Compounds'); such as small molecular compounds disrupting IL-1&#x3b2; ligand-IL-1 receptor interaction, IL-1&#x3b2; antibodies or IL-1 receptor antibodies, e.g. IL-1&#x3b2; binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1&#x3b2; binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1&#x3b2; ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Use of IL-1beta compounds

Methods of treating arthritis using IL-1&#x3b2; binding molecules

Growing community of inventors

Swampscott, MA, United States of America

Timothy Wright